SACI-IO HR+: A Randomized Phase II Trial of Sacituzumab Govitecan with or Without Pembrolizumab in Patients with Metastatic Hormone Receptor-Positive/her2-negative Breast Cancer.
JOURNAL OF CLINICAL ONCOLOGY(2024)
关键词
283-217-7597,261-492-3532-2370-7650-2700,261-492-3532-2373,261-492-199,261-566-3248-9542-7750,3282-206-3220-6287,3282-3306-4614-3760,242,1876,242,1614,1876,16,38092-33344,38092-20072,38092-34807,38092-29187,38092-24902,38092-22447,38092-20232,38092-20225
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要